Predictive efficacy of serum soluble PD-L1 on patients with metastatic renal cell carcinoma treated with Nivolumab

Predictive efficacy of serum soluble PD-L1 on patients with metastatic renal cell carcinoma treated with Nivolumab - Serum soluble PD-L1 and nibolumab in patients with renal cell carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027873

Enrollment

Registered

2017-09-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced renal cell carcinoma

Interventions

Nivolumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Metastatic or unresectable renal cell carcinoma

Exclusion criteria

Exclusion criteria: History with other malignancies Pregnant

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Overall survival Responce rate	—

Countries

Japan

Contacts

Public ContactNobuyuki Hinata

Kobe University Graduate School of Medicine Department of Urology

hinata@med.kobe-u.ac.jp078-382-6155

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026